MARKET

MREO

MREO

MEREO BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.930
+0.030
+1.03%
Opening 09:30 08/06 EDT
OPEN
2.820
PREV CLOSE
2.900
HIGH
2.930
LOW
2.820
VOLUME
2.20K
TURNOVER
--
52 WEEK HIGH
4.269
52 WEEK LOW
0.6900
MARKET CAP
198.49M
P/E (TTM)
-1.4182
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MREO stock price target is 0.1049 with a high estimate of 0.1049 and a low estimate of 0.1049.

EPS

MREO News

More
iTeos Therapeutics Begins U.S. IPO Rollout
Seeking Alpha - Article · 07/02 19:59
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
GlobeNewswire · 06/30 12:00
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
GlobeNewswire · 06/16 12:00
WORK, PD among premarket losers
Seeking Alpha - Article · 06/05 13:21
AAL, LK, SMAR and SAVA among midday movers
Seeking Alpha - Article · 06/04 16:42
Mereo Bio completes capital raise; advances etigilimab
Seeking Alpha - Article · 06/04 13:50
Mereo Bio completes $70M private placement; advances etigilimab into Phase 1b study
Seeking Alpha - Article · 06/04 13:50
AAL, NIO among premarket gainers
Seeking Alpha - Article · 06/04 13:22

Industry

Biotechnology & Medical Research
-0.15%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About MREO

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.
More

Webull offers kinds of Mereo BioPharma Group PLC stock information, including NASDAQ:MREO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MREO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MREO stock methods without spending real money on the virtual paper trading platform.